EyeYon Medical Overview
EyeYon Medical is a start-up company specializing in developing medical ophthalmic devices for complications resulting from various corneal diseases, including corneal edema. EyeYon Medical has developed exclusive technologies that have proven to have a solution to acute problems in the ophthalmic world. EyeYon Medical's flagship product is an artificial endothelial layer called EndoArt. EndoArt is a synthetic implant attached to the posterior corneal surface to treat chronic corneal edema secondary to endothelial dysfunction. The minimally invasive EndoArt is designed to replace dysfunctional endothelium to cure corneal edema, offering a safe and simple solution that will be available to anyone, anywhere. EyeYon Medical also developed the Hyper CL, an FDA-approved therapeutic contact lens for a variety of corneal conditions that require eye drop treatment.
Cumulative Funding Raised Over Time ($)
$2.6MApr 2015
$3.1MJan 2010
$11.1MMar 2017
$36.1MMar 2021
Latest News
growth-positive
/PRNewswire/ -- EyeYon Medical is proud to announce its expansion in China with the establishment of a new subsidiary, Zhuhai EyeYon Medical Technology Co.,...
EyeYon Medical has announced its expansion into China with the establishment of a new subsidiary, Zhuhai EyeYon Medical Technology Co., Ltd. This strategic move aims to address unmet needs in Chinas ophthalmology sector, particularly focusing on corneal blindness. The expansion is expected to accelerate EyeYons growth trajectory by allowing the company to better serve Chinese patients and healthcare providers. The subsidiary will focus on product localization, strategic partnerships, clinical studies, regulatory compliance, and talent acquisition. EyeYon Medical is committed to integrating its technologies into the Chinese healthcare system and supporting local communities through educational and philanthropic activities. The companys EndoArt, a synthetic corneal implant, is highlighted as a groundbreaking alternative to donor tissue.
ExpandPartnersProduct Stage
growth-positive
EyeYon Medical Appoints Dr. Sharon Bakalash MD, PhD As Chief Medical Officer
EyeYon Medical announces the appointment of Dr. Sharon Bakalash as Chief Medical Officer. Dr. Bakalash brings extensive experience in clinical development and medical affairs to the company. She will lead the clinical activity for EyeYon Medicals innovative products, including the EndoArt synthetic corneal endothelium and the HyperCL contact lens. The CEO of EyeYon Medical, Nahum Ferera, expresses his excitement about having Dr. Bakalash as a leader for the companys global clinical activity. Dr. Bakalash has a strong background in the ophthalmic space, having worked with biotechnology companies and served as a chief medical officer in the industry. She holds an MD, a PhD, and a business degree.
Management Changes
growth-positive
Israel's EyeYon Medical Receives CE Mark For Its Synthetic Implant
Israeli startup EyeYon Medical has received a CE Mark for its EndoArt implant, a synthetic implant that replaces the human endothelium to treat chronic corneal edema. The implant eliminates the need for corneal donations and offers a minimally invasive surgery option. EyeYon Medical has also raised $25 million, bringing its total capital raised to $36 million. The company plans to work closely with healthcare providers in Europe to provide the innovative solution to patients suffering from corneal edema.
CustomersInvestment
growth-positive
EyeYon Medical Announces Innovative Medical Device Designation Granted For EndoArt® In China
EyeYon Medicals EndoArt® has been granted the Innovative Device Status by Chinas Center for Medical Device Evaluation. It is the only ophthalmic device in the world to receive both Chinas Innovative Device Status and the Breakthrough Device Designation from the U.S. FDA. EndoArt® is a synthetic implant that treats chronic corneal edema, reducing the need for human donor tissue. The company has conducted clinical trials in Europe, India, and Israel, showing significant reduction in edema. EyeYon Medical plans to begin its first in-human trial in China soon. The companys investors, including Rimonci Capital, are supporting its technology advancement in China.
PartnersInvestment
growth-positive
EyeYon Medical raises $25 million for corneal implants
Israeli life sciences company EyeYon Medical has raised $25 million in a series C investment round. The funds will be used to expand the clinical trials of its flagship product, the EndoArt, a synthetic implant that treats chronic corneal edema. The implant eliminates the need for human tissue or corneal donations. EyeYon Medical aims to simplify corneal surgical procedures and address the long waiting list for available human donor corneas. The companys technology has already shown safety and efficacy in human trials. The funding round reflects investor confidence in the companys unique and disruptive technology.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $36.14M |
| Last funding | $25M |
| Stage | C |
| Rounds | 4 |
| Investors | 12 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | eye-yon.com |
Locations
5 Golda Meir St., Ness Ziona, Israel
Photos & Videos
4 item(s)
EyeYon Medical Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersCore Technology
Materials & SubstancesImplantsTags (15)
bioconvergencemedical-technologieseye-diseasesmedical-devicesminimally-invasiveophthalmologypatientslensesnon-invasivenon-surgicalclinicshealthcare-providershospitalstreatmentsoptronicsGeographic Markets
United StatesEuropeIndiaChinaEyeYon Medical Financials
$36.14M
Total funding
Undisclosed
Capital raised
$25M
Last funding
C
Funding stage
4
Total rounds
12
Investors
Cumulative Funding Raised Over Time ($)
$2.6MApr 2015
$3.1MJan 2010
$11.1MMar 2017
$36.1MMar 2021
Private Equity Funding
C Round
Mar 2021
$25M
CR-CP Life Science Fund (Lead)
,
Triventures, Quark Venture, Diamond Bio Fund , BPC, Pontifax, Rimonci Capital
B Round
Mar 2017
$8M
Rimonci Capital, Gauss Group, Pontifax, Triventures, Diamond Bio Fund
A Round
Apr 2015
$2.65M
Docor International Management, Office of the Chief Scientist, Pontifax, Triventures
Seed
Jan 2010
$488K
Sagam Group, VLX Ventures
EyeYon Medical Lifecycle
Cumulative Funding Raised Over Time
$2.6MApr 2015
$3.1MJan 2010
$11.1MMar 2017
$36.1MMar 2021
All Events
C Round
Mar 2021
$25M
CR-CP Life Science Fund (Lead)
,
Triventures, Quark Venture, Diamond Bio Fund , BPC, Pontifax, Rimonci Capital
B Round
Mar 2017
$8M
Rimonci Capital, Gauss Group, Pontifax, Triventures, Diamond Bio Fund
A Round
Apr 2015
$2.65M
Docor International Management, Office of the Chief Scientist, Pontifax, Triventures
Seed
Jan 2010
$488K
Sagam Group, VLX Ventures
EyeYon Medical News
12 articles
growth-positive
/PRNewswire/ -- EyeYon Medical is proud to announce its expansion in China with the establishment of a new subsidiary, Zhuhai EyeYon Medical Technology Co.,...
EyeYon Medical has announced its expansion into China with the establishment of a new subsidiary, Zhuhai EyeYon Medical Technology Co., Ltd. This strategic move aims to address unmet needs in Chinas ophthalmology sector, particularly focusing on corneal blindness. The expansion is expected to accelerate EyeYons growth trajectory by allowing the company to better serve Chinese patients and healthcare providers. The subsidiary will focus on product localization, strategic partnerships, clinical studies, regulatory compliance, and talent acquisition. EyeYon Medical is committed to integrating its technologies into the Chinese healthcare system and supporting local communities through educational and philanthropic activities. The companys EndoArt, a synthetic corneal implant, is highlighted as a groundbreaking alternative to donor tissue.
ExpandPartnersProduct Stage
growth-positive
EyeYon Medical Appoints Dr. Sharon Bakalash MD, PhD As Chief Medical Officer
EyeYon Medical announces the appointment of Dr. Sharon Bakalash as Chief Medical Officer. Dr. Bakalash brings extensive experience in clinical development and medical affairs to the company. She will lead the clinical activity for EyeYon Medicals innovative products, including the EndoArt synthetic corneal endothelium and the HyperCL contact lens. The CEO of EyeYon Medical, Nahum Ferera, expresses his excitement about having Dr. Bakalash as a leader for the companys global clinical activity. Dr. Bakalash has a strong background in the ophthalmic space, having worked with biotechnology companies and served as a chief medical officer in the industry. She holds an MD, a PhD, and a business degree.
Management Changes
growth-positive
Israel's EyeYon Medical Receives CE Mark For Its Synthetic Implant
Israeli startup EyeYon Medical has received a CE Mark for its EndoArt implant, a synthetic implant that replaces the human endothelium to treat chronic corneal edema. The implant eliminates the need for corneal donations and offers a minimally invasive surgery option. EyeYon Medical has also raised $25 million, bringing its total capital raised to $36 million. The company plans to work closely with healthcare providers in Europe to provide the innovative solution to patients suffering from corneal edema.
CustomersInvestment
growth-positive
EyeYon Medical Announces Innovative Medical Device Designation Granted For EndoArt® In China
EyeYon Medicals EndoArt® has been granted the Innovative Device Status by Chinas Center for Medical Device Evaluation. It is the only ophthalmic device in the world to receive both Chinas Innovative Device Status and the Breakthrough Device Designation from the U.S. FDA. EndoArt® is a synthetic implant that treats chronic corneal edema, reducing the need for human donor tissue. The company has conducted clinical trials in Europe, India, and Israel, showing significant reduction in edema. EyeYon Medical plans to begin its first in-human trial in China soon. The companys investors, including Rimonci Capital, are supporting its technology advancement in China.
PartnersInvestment
growth-positive
EyeYon Medical raises $25 million for corneal implants
Israeli life sciences company EyeYon Medical has raised $25 million in a series C investment round. The funds will be used to expand the clinical trials of its flagship product, the EndoArt, a synthetic implant that treats chronic corneal edema. The implant eliminates the need for human tissue or corneal donations. EyeYon Medical aims to simplify corneal surgical procedures and address the long waiting list for available human donor corneas. The companys technology has already shown safety and efficacy in human trials. The funding round reflects investor confidence in the companys unique and disruptive technology.
Investment
growth-positive
מבט לעתיד: המיזם הישראלי שפיתח שתל מלאכותי לעין
Israeli startup EyeYon Medical has developed an artificial eye implant to address the long waiting times for corneal transplantation surgeries. The company aims to provide a safe and simple solution that will be available to everyone. The implant, called EndoArt, replaces the damaged layer of the cornea and has shown promising results in human trials. EyeYon Medical plans to expand its clinical trials and seek regulatory approval in Europe and the US. The company is based in Nes Ziona Science Park and currently employs ten people. Its goal is to bring about a significant change in the field of corneal transplantation and improve vision for millions of people worldwide.
Customers
growth-positive
Breakthrough Device Designation Received From the FDA for EndoArt®
EyeYon Medical, a start-up company developing ophthalmic products, has received Breakthrough Device Designation from the FDA for its Artificial Endothelial Layer implant called EndoArt®. The implant is designed to treat chronic corneal edema secondary to endothelial dysfunction. It aims to replace dysfunctional endothelium in patients where human donor tissue has failed to resolve the edema. The Breakthrough Device Designation will accelerate the development and review process of EndoArt®, providing timely access to the device for patients and healthcare providers. EyeYon Medical aims to improve the quality of life for millions of patients suffering from corneal edema.
Customers
growth-positive
Ophthalmic device co EyeYon Medical raises $6.5m
Israeli ophthalmic device company EyeYon Medical has raised $6.5m in a funding round led by China-based venture capital fund Rimonci Capital and co-investor Gauss Group. Existing investors Triventures and Pontifax also participated in the round, along with a grant from Israels Chief Scientist. EyeYon Medical, which specialises in medical ophthalmic devices, plans to use the funding to expand its product platform, complete the EndoArt first in human safety and performance study, obtain regulatory approval for EndoArt, continue Hyper CL development for additional indications as a drug delivery platform and grow sales and marketing activities globally.
InvestmentExpand
growth-positive
Link: FDA Approves EyeYon Corneal Edema Treatment
EyeYon, an Israeli company, has received US marketing authorization for its medical contact lens, Hyper-CL, used for the treatment of corneal edema. The lens is designed with a reservoir that allows hypertonic drops to have a longer contact time with the cornea, improving the extraction of excess fluids. The product is commercially available in Europe and will soon be available in the US. It can be prescribed for daily wear and can also provide optical correction during the healing process. The technology also has potential for medication delivery for other ocular conditions.
Customers
growth-positive
Israeli eye treatment co EyeYon Medical raises $3.6m
Israeli medical device start-up EyeYon Medical has raised $3.6 million in funding. The funds will be used to develop the companys corneal edema treatment products. EyeYon Medicals leading product is a hyper-osmotic contact lens that absorbs corneal fluids and alleviates symptoms. The company also has another product in development that aims to cure the disease entirely. The investment will be used for additional clinical trials, global market penetration, and product development.
InvestmentExpand
growth-positive
Trailblazing is Israel's last name
EyeYon Medical, a medical technology company based in Jerusalem, has developed an innovative contact lens treatment for eye diseases, particularly corneal edema. The treatment, which consists of a disposable contact lens that acts as a pump to extract fluids from the cornea, has passed clinical testing in Israel and received CE approval to market in Europe. The company is also working on a hydrophobic implant to prevent corneal edema and eliminate the need for corneal transplants. The article highlights the technological innovation and potential impact of EyeYon Medicals treatment on improving the quality of life for patients with corneal edema.
Customers
growth-positive
EyeYon's noninvasive answer to a common eye problem
Israeli startup EyeYon Medical has developed a patented therapeutic contact lens, Hyper CL, to relieve symptoms of corneal edema. The lens extracts fluids by osmosis and smooths the surface of the cornea, improving vision and protecting from infection. The Hyper CL has already received the European CE Mark and is expected to enter the market in 2014. EyeYon is also developing a silicon film implant, DSPEK, to prevent corneal edema during or after cataract and transplant surgery. The potential market for EyeYons products is estimated to be worth $500 million worldwide. The company is currently financed by various investors and is chaired by Elka Nir.
Customers
EyeYon Medical Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 30 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
EyeYon Medical Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514509603 |
| Crunchbase | eyeyon |
| Phone | +972737803607 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-21T00:00:00.000Z |
| Created | 2014-07-17T00:00:00.000Z |